Clinical Trial: A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer

U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07597629) titled 'A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer' on May 13.

Brief Summary: This is an open-label, multicenter Phase II clinical study conducted in subjects with advanced breast cancer.

Study Start Date: May 30

Study Type: INTERVENTIONAL

Condition: Advanced Breast Cancer

Intervention: DRUG: SYS6023

SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.

DRUG: HB1901

HB1901 is a specific mTOR inhibitor, administered via intravenous infusion.

DRUG: KN026

KN026 is an antibody targeting HER2, administered via intravenous infusion.

Recruitment Status: NO...